Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Truist??

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Oct 20, 2022 2:19pm

99 Views

Post# 35037012

RE:RE:RE:Truist??

I know that would really suck...Maybe Soleus is the Buyer!!

Wino115 wrote: I'm not sure telling an institution you can round up a nice chunk from top mgmt selling is a very convincing argument. In the past I recall a situation someone described of a forced seller and the CFO was alerted to the position and tried to facilitate a placement of it.

palinc2000 wrote:
Exercise of options?